709 Phase II Study to assess the safety and efficacy of the CLEVER-1 antibody bexmarilimab in combination with PD-1 blockade in patients with advanced solid tumors – BEXCOMBO | Zendy

AI Assistant Blog Pricing

709 Phase II Study to assess the safety and efficacy of the CLEVER-1 antibody bexmarilimab in combination with PD-1 blockade in patients with advanced solid tumors – BEXCOMBO

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.